Document Type
Article
Publication Date
11-13-2017
College/Unit
School of Medicine
Abstract
Solitary fibrous tumor of the pleura is a rare and usually benign primary neoplasm arising from mesenchymal cells of the submesothelial tissue. We present here the case of a patient diagnosed with CD34-positive advanced malignant solitary fibrous tumor of the pleura whose disease failed to respond to combination cytotoxic chemotherapy agents, but demonstrated a prompt near-complete response to checkpoint blockade treatment using the anti-programmed death (PD)-1 monoclonal antibody pembrolizumab, based on tumor molecular profiling revealing tumoral expression positivity for both programmed death-ligand 1 (PD-L1) and PD-1. The patient experienced minimal adverse effects from the treatment with durable favorable response lasting up to cycle 26.
Digital Commons Citation
Boothe, James T.; Budd, G. Thomas; Smolkin, Matthew B.; and Ma, Patrick C., "Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura" (2017). Clinical and Translational Science Institute. 722.
https://researchrepository.wvu.edu/ctsi/722
Source Citation
Boothe JT, Budd GT, Smolkin MB, Ma PC. Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura. Case Reports in Oncology. November 2017:998-1005. doi:10.1159/000484041